Results 101 to 110 of about 6,813 (202)

Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis

, 2018
Background Lymphangioleiomyomatosis is a rare disease caused by unregulated activation of mammalian target of rapamycin (mTOR) signalling pathway. Sirolimus showed efficacy in a phase 3 trial of patients with lymphangioleiomyomatosis, but the optimal ...
Jung Jin Hwang, Hee-Young Yoon, Dong Soon Kim, Jin Woo Song   +3 more
core   +1 more source

Pneumothorax as a Presentation of Tuberous Sclerosis-Associated Lymphangioleiomyomatosis

European Journal of Case Reports in Internal Medicine, 2019
Tuberous sclerosis complex (TSC) is a rare, autosomal dominant disorder with a recognized phenotypic variability with clinical manifestations developing continuously throughout life. The follow-up of TSC patients is challenging.
Duarte Lages Silva, Pedro Pinto, Miguel Costa, Rosana Maia, Carmelia Rodrigues   +4 more
doaj   +1 more source

Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.

, 2012
Lymphangioleiomyomatosis is a rare cause of pneumothorax in women. We present the case of a 48-year-old woman with lymphangioleiomyomatosis, who had never had a pneumothorax prior to commencing chemotherapy for breast cancer.
Tryfonopoulos, Dimitrios, Sukor, Sumainizah, McDonnell, Timothy J, Kelly, Emer, Keane, Michael P, Mhurchu, Elaine Ni   +5 more
core  

Lymphangioleiomyomatosis presenting with perirenal hemorrhage

, 2015
Lymphangioleiomyomatosis (LAM) is a rare debilitating disease of unknown etiology, classically described as almost exclusively affecting women of childbearing age.
N Peters, K Decaestecker, PETERS, NIELS, S Dekeyzer, Gosselin, Robert, Dekeyzer, Sven, De Visschere, Pieter, Decaestecker, Karel, P Smeets, R Gosselin, Smeets, Peter, P De Visschere   +11 more
core   +1 more source

Drugs extracted from MalaCards for “lymphangioleiomyomatosis”.

Table B. Reactome Pathways according to MalaCards for “lymphangioleiomyomatosis”. Table C. Wiki pathways according to MalaCards for “lymphangioleiomyomatosis”. Table D. KEGG and other pathways from MalaCards for “lymphangioleiomyomatosis”. Table E.
George M. Spyrou (8813291), Nestoras Karathanasis (737388), Anastasis Oulas (8813288), Kyriaki Savva (18405716)   +3 more
core   +1 more source

Case report: If it is not asthma—think of lymphangioleiomyomatosis in younger female patients

Frontiers in Medicine
Lymphangioleiomyomatosis (LAM) is a rare lung disease predominantly affecting women, and it is characterized by the proliferation of smooth muscle cells and cystic lung destruction.
Malene Helligsø Kirkeby, Elisabeth Bendstrup, Elisabeth Bendstrup, Hanne Krogh Rose   +3 more
doaj   +1 more source

Persistent chylothorax in lymphangioleiomyomatosis treated by intrapleural instillation of povidone.

, 2008
Lymphangioleiomyomatosis (LAM) is a rare, idiopathic disease affecting young women often complicated by refractory and difficult to manage chylothorax.
REA, FEDERICO, RIZZARDI G, LOY M, REA F, MARULLI, GIUSEPPE, MARULLI G.   +5 more
core   +1 more source

Lymphangioleiomyomatosis (LAM) [PDF]

American Journal of Respiratory and Critical Care Medicine, 2018
Ali, Ataya, Mark, Brantly, Leonard, Riley   +2 more
openaire   +2 more sources

Lung transplantation for cystic lung diseases: lymphangioleiomyomatosis, histiocytosis x, and sarcoidosis.

, 2001
Lung transplantation for respiratory failure due to lymphangioleiomyomatosis, histiocytosis X, and sarcoidosis is a therapeutic option in selected patients.
Boehler A
core   +1 more source

Sporadic lymphangioleiomyomatosis [PDF]

QJM, 2014
W-C, Chen, T-C, Shen, C-Y, Tu
openaire   +2 more sources